Innogenetics Optimistic On HCV Patent Trial

Law360, New York (August 29, 2006, 12:00 AM EDT) -- With the patent infringement trial underway, Belgian biotechnology company Innogenetics remains cautiously optimistic that it will defeat Abbott Laboratories in its battle over a hepatitis C virus genotyping patent.

The company expressed confidence over the outcome of the trial on Tuesday, a day after a judge asserted that the U.S. group infringed one of Innogenetics’ patents.

"We feel strongly encouraged by the course of the proceedings to date and we are very optimistic that the validity of our issued U.S. patent will be confirmed by the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.